Frontlight ResearchEarly access
Taking peoplePhase 2
The Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients
Key facts
- Who runs it
- Ain Shams University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 20 Nov 2025
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Midazolam + Ketamine
- Dexmedetomidine (DEX)
- Record updated
- 9 April 2026
Who can take part
- Age
- 3 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age from 3 to 16 years
- Both sexes
- Patients classified as American Society of Anesthesiologists (ASA) Physical -Status I-II
- Patients scheduled for elective burn-related procedures (e.g., burn dressing changes or minor interventions)
Who cannot take part
- Patients receiving or requiring high doses of inotropes and/or vasopressors intraoperatively or postoperatively
- Known allergy or hypersensitivity to any of the study medications (midazolam, ketamine, or dexmedetomidine)
- Presence of immunological or hematological disorders
- History of epilepsy, developmental delay (mental retardation), or neurological deficits
- Preoperative hemodynamic instability, defined as uncontrolled hypertension, hypotension, or bradycardia
- Refusal or inability to provide written informed consent from parent or legal guardian
- Presence of hepatic dysfunction
- Presence of renal dysfunction
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 16 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to compare the effects of dormicum-ketamine versus dexmedetomidine on postoperative emergence delirium in pediatric patients undergoing deep sedation for burn-related procedures
The 2 groups in the trial
- Midazolam - Ketamine GroupTreatment being tested
Drug
Treatment: Midazolam + Ketamine
- DexmedetomidineTreatment being tested
Drug
Treatment: Dexmedetomidine (DEX)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07519863, who can take part
- Record updated
- 9 April 2026